
US President Joe Biden’s tougher regulatory stance on big corporate mergers has fueled a rise in investor bets on some deals not being completed, reported Reuters.
Spreads between deal prices and the share prices of acquisition targets widened this week after the US Federal Trade Commission stated on Tuesday, August 3, that a surge in mergers and acquisitions (M&A) would delay antitrust reviews, and that companies that did not wait for their outcome completed their deals at their own risk.
Related: Biden’s Executive Order and the Shifting US Antitrust Landscape
On Wednesday, the Information reported that the US Department of Justice was weighing a lawsuit to block UnitedHealth Group’s nearly US$8 billion deal to acquire healthcare analytics and technology vendor Change Healthcare. Such a move would follow its lawsuit to block Aon’s US$30 billion acquisition of Willis Towers Watson, which resulted in the insurance brokerages abandoning their deal last month.
“The fact that spreads have widened is the understatement of the year,” said Roy Behren, managing member of Westchester Capital Management, which currently has US$5.1 billion of assets under management, 85% of which is invested in merger arbitrage.
Widened spreads include the proposed US$33.6 billion deal between railroad operators Canadian National Railway and Kansas City Southern, as both companies await approval from the Surface Transportation Board. Shares of Kansas City are currently trading at US$262 apiece, well below the agreed cash-and-stock deal of US$269 per share.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas